Health (Western Australian Cancer Register) Regulations 2011

These regulations establish a mandatory, statewide reporting system for cancer diagnoses in Western Australia. Mechanically, they do three things. First, they prescribe cancer as a notifiable condition under Part IXA of the Health (Miscellaneous Provisions) Act 1911, which is the enabling provision that allows the government to collect data on specified diseases. Second, they create the Western Australian Cancer Register, a central database managed by the Chief Health Officer, and specify its permissible uses: monitoring case numbers, planning and evaluating cancer control services, compiling statistics, and conducting research into causes, prevention, screening and treatment (regulation 10(4)). Third, they impose notification duties on specific health practitioners and hospitals, backed by escalating fines for non-compliance.

The notification regime is not a single channel. Regulation 5 requires examining specialists (pathologists, haematologists, clinical biochemists) to notify the Chief Health Officer within 30 days when a specimen indicates or is suggestive of cancer. This includes a separate duty for lymph node specimens taken during cancer staging or treatment, even if no malignant cells are found. Regulation 6 requires radiation oncologists to notify within 30 days of first treating a person with ionising radiation or accelerated atomic particles. Regulation 7 requires ophthalmologists to notify within 30 days of diagnosing an ocular melanoma without a surgical biopsy or pathology test. Regulation 8 requires the chief executive officer of a hospital to notify within 30 days of a patient’s discharge if the patient was treated for cancer, unless the CEO reasonably believes the cancer was already diagnosed pathologically in Western Australia under regulation 5(1). Regulation 9 gives the Chief Health Officer a broad power to request information from any medical practitioner or hospital CEO about a person known to have or be treated for cancer, even if no prior notification was made.

All notified information goes onto the Register. The regulations also govern disclosure: a person with access to the Register may not disclose information without authority (regulation 11). The Chief Health Officer may authorise disclosure for approved research (under NHMRC guidelines), to the Australian Institute of Health and Welfare for prescribed purposes, in urgent cases for diagnosis or treatment where patient consent is impracticable, or to a corresponding officer in another jurisdiction if the patient’s usual residence is there (regulation 12). Non-identifying information may be disclosed for any of the four Register purposes. The 2018 amendment deleted former paragraph 12(1)(b), which had allowed disclosure to the Cervical Screening Register.

Finally, the regulations repeal the earlier Health (Notification of Cancer) Regulations 1981, consolidating and updating the reporting framework. The commencement was staggered: regulations 1 and 2 on publication in the Gazette, the rest 42 days later.

Cancer. The definition in regulation 3 is deliberately broad and goes beyond common understandings of the term. It means “a neoplastic growth of human tissue which if unchecked has the potential to spread to adjacent tissue and beyond its site of origin”. The definition expressly includes not only malignant neoplasms (invasive or in situ) but also benign neoplasms of the brain, spinal cord, cranial nerves, or intracranial space; gastrointestinal stromal tumours; carcinoid and neuroendocrine tumours; phaeochromocytoma and paraganglioma; ovarian neoplasms of borderline malignancy; and a wide range of lymphohaematopoietic neoplasms including leukaemia, lymphoma, myelodysplastic syndrome, refractory anaemia, chronic myeloproliferative disorders, and myelofibrosis. Notably, primary invasive or in situ basal cell carcinoma and squamous cell carcinoma of the skin are excluded. This means a pathologist reporting a skin BCC does not need to notify. But many conditions that a clinician might not label “cancer” in conversation , such as myelodysplastic syndrome or a benign meningioma , are caught.

Notifying practitioners. The regulations identify four classes of notifier: examining specialists (pathologists, haematologists, clinical biochemists who examine specimens), radiation oncologists, ophthalmologists, and chief executive officers of hospitals. The duties are distinct and may overlap. For example, a pathology report may trigger notification by the specialist under regulation 5, and if the same patient is later discharged from hospital after treatment, the hospital CEO must also notify unless they reasonably believe a prior pathological notification occurred. This creates potential double reporting but with an exemption for hospitals to avoid duplication.

Notified information. The precise data points are set out in Schedule 1 and include: name, address, sex, date of birth, place and country of birth, Indigenous Australian status, date of diagnosis, place of residence at diagnosis, date of admission or outpatient consultation, primary site, morphological subtype, stage or extent, outcome of screening tests, and method of diagnosis. Regulation 5(3) also requires the referring medical practitioner’s name and the hospital name and address if applicable. The definition of “identifying information” is any information from which identity is apparent or can reasonably be ascertained. This matters because disclosure of identifying information is more restricted than non-identifying data.

The Register. The Western Australian Cancer Register is kept by the Chief Health Officer in a manner and form the CHO determines (regulation 10(5)). It must contain all notified information. It may also contain information from corresponding officers in other states or territories, and any other information the CHO considers appropriate for the four stated purposes. The purposes are limited to monitoring, planning, evaluating services, compiling general or statistical information, and research. This is not a general health database; its uses are tied to cancer control.

Examining specialists. Pathologists, haematologists, and clinical biochemists in private and public laboratories are the primary notifiers. They must have systems to identify when a specimen indicates or suggests cancer, and to forward a copy of the report plus additional patient data to the Chief Health Officer within 30 days. This affects every pathology practice in Western Australia that handles tissue or blood specimens. The duty extends to lymph node specimens taken for staging or treatment, even if no malignant cells are found , a notable burden because many such specimens will be benign but still require notification. For a private pathology company, the compliance cost includes staff time, data entry, record keeping, and potential IT integration with the Register. There is no de minimis exemption; a small rural single-doctor pathology service faces the same obligation as a large metropolitan lab.

Radiation oncologists. Any practitioner who treats a person with ionising radiation or accelerated atomic particles must notify within 30 days of first treatment. This captures the first encounter. The data required includes not only patient identifiers but also type and presumed primary site of cancer and referring doctor. This duty applies to both public hospital departments and private radiation oncology centres.

Ophthalmologists. They have a specific duty only for ocular melanoma diagnosed without surgical biopsy or pathology. This is a narrow niche, but relevant for the few cases where ophthalmologists diagnose melanoma clinically (e.g., by fundoscopy and imaging) and do not excise or biopsy. They must use the full Schedule 1 data.

Hospital CEOs. Hospitals that treat cancer patients must notify upon discharge unless the cancer was already diagnosed pathologically in WA. This affects all public and private hospitals. The CEO is the person responsible for day-to-day operations, but in practice the duty will be delegated to health information managers, medical records staff, or cancer registries. The hospital must track which patients were treated for cancer, determine whether a pathological notification has already occurred, and if not, send the Schedule 1 information within 30 days of discharge. This creates an administrative burden on hospital coding and discharge summary processes.

Medical practitioners generally. Under regulation 9, any medical practitioner can be required by the Chief Health Officer to provide information about a patient known to have or be treated for cancer. This is a broad residual power. A GP who is not otherwise a notifier may receive a written request and must comply within 30 days. This affects private practitioners who may have no existing relationship with the Register.

Duty to notify within 30 days (examining specialists, regulation 5). An examining specialist who becomes aware that a specimen indicates or is suggestive of cancer must give the CHO a copy of the report and any missing information from regulation 5(3). This includes full name, address, sex, date of birth, Indigenous status, referring doctor, and hospital if applicable. The same duty applies to lymph node staging specimens even if no malignancy. The 30-day clock starts when the specialist becomes aware , not when the report is signed or issued. This creates potential ambiguity if a result is reviewed later.

Duty to notify after first radiation treatment (regulation 6). A radiation oncologist must notify within 30 days of first treating a person with ionising radiation or accelerated atomic particles. The information required is similar but also includes type and presumed primary site. The CHO may also request a copy of any pathology report the radiation oncologist has received, and the oncologist must comply within 30 days.

Duty to notify for ocular melanoma without pathology (regulation 7). The ophthalmologist must use the full Schedule 1 data.

Duty of hospital CEO to notify on discharge (regulation 8). The CEO must notify within 30 days of discharge for any patient treated for cancer, unless they reasonably believe the cancer was diagnosed pathologically in WA under regulation 5(1). The “reasonable belief” standard places a burden on the hospital to inquire about prior pathology reports.

Duty to respond to CHO request (regulation 9). Any medical practitioner or hospital CEO who receives a written request from the CHO must comply within 30 days. There is no limit on how many requests can be made. This duty can apply to practitioners who have no prior obligation to notify.

Right of the CHO to keep the Register and determine its form (regulation 10). The CHO has significant discretion over the Register’s format and content, including the ability to add information from other sources.

Right to authorise disclosure (regulation 12). The CHO may authorise disclosure of information for approved research, to the AIHW, in urgent care settings, or to interstate officers. Non-identifying information can be disclosed for any Register purpose. This right is discretionary.

Right of patients to consent to disclosure (regulation 11(a)). Written consent overrides the general prohibition on disclosure. This is the only individual right explicitly recognised in the regulations for patients.

The penalty structure is uniform across all notification offences: a maximum fine of $1,000 and a minimum fine that escalates with the number of offences. For a first offence the minimum is $100, for a second offence $200, and for a third or subsequent offence $500 (see regulations 5, 6, 7, 8, 9, and 11). This is a criminal penalty, not a civil administrative one. The fine range gives the court some discretion, but the minimum floor removes the option of a nominal penalty for a first breach.

The penalties are relatively modest, especially compared to the cost of compliance for a large hospital or pathology chain. A $100 minimum fine is unlikely to be a strong deterrent for a busy pathologist who misses a 30-day deadline. However, the threat of a criminal conviction, even for a minor fine, may have reputational and professional consequences for health practitioners. There is no provision for infringement notices or on-the-spot fines; enforcement would require prosecution in a magistrates court, which imposes costs on the state and may discourage frequent enforcement.

The maximum fine of $1,000 has not been adjusted since 2011 and has not kept pace with inflation. In real terms, the penalty has diminished. This may reduce the incentive for compliance, particularly for organisations that can absorb a small fine as a cost of doing business.

There is no provision for imprisonment or for suspension of a practitioner’s registration. The offence is strict? The regulations do not specify a mental element (e.g., knowingly, intentionally). Under general criminal law principles, a penalty provision without a fault element is likely to be interpreted as requiring proof that the person did the act (e.g., failed to notify) but not that they intended to break the law. This makes enforcement easier for the prosecution, but also means a specialist who genuinely did not realise a specimen indicated cancer could still be liable.

Enforcement is entirely dependent on the Chief Health Officer’s resources. The regulations do not require auditing or proactive checking. Notification relies on self-reporting. A practitioner who simply never notifies may go undetected unless a patient’s record from another source (e.g., hospital discharge or another specialist’s notification) triggers a cross-check. The CHO has the power to request information under regulation 9, which could be used to follow up suspected non-compliance, but this is ad hoc.

The offence for unauthorised disclosure (regulation 11) has the same penalty range. This applies to any person who has access to the Register in the course of duty and discloses without authority. For a public servant or researcher, this could be a serious breach, but the maximum penalty is low.

These regulations are made under the Health (Miscellaneous Provisions) Act 1911, specifically Part IXA which deals with notification of diseases. The Act itself is not provided, but the regulations explicitly prescribe cancer as a condition to which that Part applies (regulation 4). This means the notification framework sits within a broader state legislative scheme that may include other notifiable diseases.

The regulations incorporate definitions from the Health Services Act 2016. “Hospital” and “health service provider” are defined by reference to that Act. As a result, any amendment to the Health Services Act definitions flows through to these regulations without direct amendment. For example, the 2016 consequential amendment updated the definition of “hospital” when the Health Services Act replaced earlier health legislation.

The regulations refer to the Commonwealth Australian Institute of Health and Welfare Act 1987 for the establishment of the AIHW. The CHO may disclose information to the AIHW but only if satisfied it is solely for a Register purpose. This allows federal cancer statistics to be compiled from WA data, but it is not a mandatory transfer; it is at the CHO’s discretion.

The research disclosure pathway in regulation 12(1)(a) requires approval in accordance with guidelines issued under the National Health and Medical Research Council Act 1992 (Cth). This means that researchers seeking identifying data must have their research proposal reviewed by a human research ethics committee operating under NHMRC standards. This is a common requirement in health research, and the regulations do not create a separate ethics framework.

The 2018 amendment (Health Regulations Amendment (Cervical Screening Register) Regulations 2018) deleted former regulation 12(1)(b), which had allowed disclosure to the Cervical Screening Register. This means that after April 2018, information from the Cancer Register can no longer be disclosed to the Cervical Screening Register under these regulations, though it might be possible under another written law. The reason for the deletion is not stated in the source, but it likely reflects a policy decision to separate the registers or to rely on a different legal basis.

Regulation 11(c) allows disclosure if authorised or required under another written law. This is a saving provision that acknowledges other state or Commonwealth laws may compel or permit disclosure. For example, a court order, a subpoena, or another health Act might require the release of Register data. The regulations do not override those other laws.

The regulations were originally made in 2011 and published in the Gazette on 29 April 2011. The operative provisions commenced on the 42nd day after publication, so around 10 June 2011. They replaced the Health (Notification of Cancer) Regulations 1981.

First amendment: Health Services (Consequential Amendments) Regulations 2016, effective 1 July 2016. This was a machinery amendment to update definitions following the enactment of the Health Services Act 2016. It changed the definition of “health service provider” and “hospital” to refer to the new Act. It also likely updated references to “chief executive officer” to align with the new terminology, though the text of this amendment is not fully reproduced; only the citation and date are given.

Second amendment: Health Regulations Amendment (Public Health) Regulations 2016, Part 26, effective 24 January 2017. This amendment further updated definitions. It amended regulation 3 (terms used) and regulation 5(3) (information to be notified) and regulation 10 (Register). It also updated the penalty provisions? The source shows that several regulations were amended on 10 January 2017, including regulation 3, 5, 6, 7, 8, 9, 10, and 12. The precise changes are not detailed, but the compilation table indicates that these amendments were part of a broader set of public health regulation changes.

Third amendment: Health Regulations Amendment (Cervical Screening Register) Regulations 2018, Part 3, effective 11 April 2018. This amendment deleted regulation 12(1)(b), which had allowed disclosure to the Cervical Screening Register. The reason for deletion is not stated, but it may reflect the creation of a separate National Cancer Screening Register or a decision to restrict cross-register data sharing.

The regulations have not been amended since 2018. They remain in force as at the latest compilation date shown in the notes.

The source text does not refer to any court cases concerning these regulations. As a compiled statutory instrument without a reported case list, we cannot assume any litigation has occurred. It is possible that no proceedings have been taken on these specific regulations. The penalty amounts are low and the subject matter (mandatory cancer notification) is unlikely to provoke frequent legal challenges. Prosecutions for non-compliance would be in the magistrates court and may not be reported in accessible legal databases.

However, one could imagine potential litigation under related laws. For example, if the CHO authorised disclosure of identifying information for research and a patient objected, there could be a challenge based on privacy or on the interpretation of “approved research” under regulation 12(1)(a). But no such cases are documented in the regulations.

The regulations themselves are purely facilitative; they create obligations but do not create a private right of action. A patient aggrieved by disclosure would have to rely on other causes of action (e.g., breach of confidence, privacy tort, or administrative law review of the CHO’s decision). There is no evidence of any such claim succeeding.

The definition of “cancer” is much broader than what most clinicians or laypeople would consider cancer. It includes benign brain tumours, myelodysplastic syndrome, gastrointestinal stromal tumours, neuroendocrine tumours, and even conditions like refractory anaemia or idiopathic thrombocythaemia. A pathologist who sees a report stating “myelodysplastic syndrome” or “benign meningioma” might not think of it as a cancer notification obligation, but the regulations require notification. The exclusion only applies to basal cell and squamous cell carcinomas of the skin. This breadth means many more notifications than the public might expect.

The notification duty under regulation 5(2) for lymph node specimens taken in staging or treatment applies even if no malignant cells are found. So a sentinel lymph node biopsy that is negative still requires notification. The purpose appears to be to track staging procedures, but the regulation does not require any cancer diagnosis for that notification. It is triggered by the act of examining the lymph node in a cancer context.

The 30-day deadline runs from when the specialist “becomes aware” of the specimen’s indication of cancer. This could be at the time of microscopy or when the report is typed. Keeping an audit trail of awareness is important.

The hospital CEO’s exemption from notification under regulation 8(2) applies only if they “reasonably believe that the cancer was diagnosed in Western Australia in the circumstances described in regulation 5(1)”. This means the cancer must have been diagnosed pathologically in WA. If the diagnosis was made clinically without pathology (e.g., by radiology), or made interstate, the hospital must notify. This catches cases where a patient is diagnosed elsewhere and then treated in a WA hospital.

Regulation 9 gives the Chief Health Officer an open-ended power to demand information from any medical practitioner about any person with cancer. There is no limit on frequency or scope. A practitioner could receive multiple requests and must comply within 30 days each time. The penalty for non-compliance applies per request.

The penalty structure is peculiar: it sets a maximum of $1,000 but also a minimum. The minimum rises with repeat offences. This removes judicial discretion to impose a very low fine (e.g., $1) for a first offence. It also means that if a court finds an offence but considers a low penalty appropriate, it cannot go below $100. This might encourage contesting the penalty rather than pleading guilty.

Disclosure for research under regulation 12(1)(a) requires approval “in accordance with the guidelines for the conduct of medical research involving humans issued in compliance with the National Health and Medical Research Council Act 1992 section 10”. This is an indirect reference to the NHMRC’s National Statement on Ethical Conduct in Human Research. A researcher must have ethics approval, but the CHO also has discretion. The CHO could refuse to authorise disclosure even if ethics approval is obtained. There is no appeal mechanism in these regulations.

For an examining specialist (pathologist, haematologist, clinical biochemist), compliance requires a systematic process. Upon signing off a report that indicates or suggests cancer (under the broad definition), the specialist must within 30 days send the Chief Health Officer a copy of that report and the additional patient data listed in regulation 5(3): full name, address, sex, date of birth, Indigenous status, referring practitioner, and hospital if patient is an inpatient. If the specimen is a lymph node taken in cancer staging or treatment, the notification is required even if the specimen is negative. The easiest compliance method is to integrate this into the laboratory information system (LIS) to automatically flag certain diagnoses and send an electronic notification to the CHO. If the LIS cannot handle the full data set, a manual system must be used. The practitioner should keep a log of notifications sent, including dates of awareness and dates of notification.

For a radiation oncologist, the trigger is the first treatment session. The oncologist must within 30 days send patient identifiers plus type and presumed primary site, referring doctor, and hospital. Again, a system prompt on the treatment record or billing system can help. The oncologist should also be prepared to provide a copy of any pathology report on request from the CHO under regulation 6(2).

For an ophthalmologist diagnosing ocular melanoma without surgical biopsy, the notification must include all items in Schedule 1. Because this is a rare occurrence, the practice should have a pro forma ready.

For a hospital chief executive officer, the duty arises when a patient is discharged after being treated for cancer. The CEO must notify within 30 days of discharge unless they reasonably believe the cancer was already diagnosed pathologically in WA. The hospital should query its pathology department or records to see if a report matching the diagnosis exists. If not, the CEO must send Schedule 1 data. The hospital should integrate this into its discharge summary and medical records workflow, perhaps using cancer registry staff. The CEO can delegate, but the legal obligation remains with the CEO.

For any medical practitioner or CEO who receives a request from the CHO under regulation 9, the response must be within 30 days. The request will specify the information needed (Schedule 1). The practitioner should ensure the request is logged and fulfilled.

In all cases, the information must be sent in writing (regulation 5, 6, 7, 8, 9 all specify “notify … in writing”). The CHO may have a preferred form (electronic or paper). Compliance should follow whatever channel the CHO directs.